ArticleDiabetes care2023

Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes.

Alexander Kutz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.